Celyad Oncology SA (NASDAQ:CYAD) was the recipient of a large drop in short interest in the month of December. As of December 31st, there was short interest totalling 18,600 shares, a drop of 63.7% from the December 15th total of 51,300 shares. Based on an average daily trading volume, of 948,700 shares, the short-interest ratio is currently 0.0 days. Currently, 0.1% of the company's stock are sold short.
Several brokerages have recently weighed in on CYAD. Zacks Investment Research raised shares of Celyad Oncology from a "hold" rating to a "buy" rating and set a $4.25 price target for the company in a research note on Tuesday, December 28th. HC Wainwright decreased their price target on shares of Celyad Oncology from $15.00 to $13.00 and set a "buy" rating for the company in a research note on Friday, December 10th. UBS Group cut shares of Celyad Oncology from a "neutral" rating to a "sell" rating in a research note on Wednesday, December 22nd. Finally, Wells Fargo & Company cut their price target on Celyad Oncology from $20.00 to $11.00 and set an "overweight" rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $9.42.
An institutional investor recently bought a new position in Celyad Oncology stock. OLD Mission Capital LLC bought a new stake in Celyad Oncology SA (NASDAQ:CYAD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,323 shares of the company's stock, valued at approximately $60,000. OLD Mission Capital LLC owned about 0.07% of Celyad Oncology at the end of the most recent reporting period. 1.83% of the stock is currently owned by institutional investors.
NASDAQ:CYAD opened at $3.85 on Friday. The stock's 50-day moving average is $4.03 and its 200-day moving average is $4.28. Celyad Oncology has a 1-year low of $3.53 and a 1-year high of $9.00.
About Celyad Oncology
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms.
Read More: How is an ETF different from a mutual fund?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Celyad Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celyad Oncology wasn't on the list.
While Celyad Oncology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here